|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...113114115116117118119120121122123...156157» |
- |||||||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
New P3 trial, Combination therapy, Monotherapy: A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 11, 2013
P3, N=100, Recruiting, Sponsor: Hoffmann-La Roche
- |||||||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
New P3 trial, Combination therapy, Monotherapy: A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants (clinicaltrials.gov) - Sep 11, 2013
P3, N=225, Recruiting, Sponsor: Hoffmann-La Roche
- Enrollment open: Arthritis Health Journal Proof of Concept Study (clinicaltrials.gov) - Sep 11, 2013
P=N/A, N=50, Recruiting, Sponsor: University of British Columbia
Not yet recruiting --> Recruiting
- | Enrollment closed: Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in Type 1 Diabetes (clinicaltrials.gov) - Sep 11, 2013
P2, N=24, Active, not recruiting, Sponsor: Rabin Medical Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- New P3 trial: Safety and Efficacy of Fingolimod in MS Patients in China (clinicaltrials.gov) - Sep 10, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
- Tzield (teplizumab-mzwv) / Sanofi
Trial completion: AbATE: Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes (clinicaltrials.gov) - Sep 10, 2013
P2, N=83, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment open, Combination therapy, Monotherapy: A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants (clinicaltrials.gov) - Sep 9, 2013
P3, N=225, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P4 trial: Protection Against Pneumococcal Infection in Children With T1DM (clinicaltrials.gov) - Sep 9, 2013
P4, N=50, Recruiting, Sponsor: University of Oxford
- |||||||||| Plegridy (PEG-interferon ?-1a) / Biogen
New P3 trial: Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-?) Therapies to Peginterferon Beta-1a (BIIB017) (clinicaltrials.gov) - Sep 9, 2013
P3, N=200, Recruiting, Sponsor: Biogen Idec
- Enrollment closed: Artificial Pancreas Control System in an Outpatient Setting (clinicaltrials.gov) - Sep 9, 2013
P2, N=16, Active, not recruiting, Sponsor: Legacy Health System
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan (clinicaltrials.gov) - Sep 9, 2013
P=N/A, N=684, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Observational data, Enrollment change: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT) (clinicaltrials.gov) - Sep 8, 2013
P=N/A, N=1240, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed N=200 --> 1240
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Observational data: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT) (clinicaltrials.gov) - Sep 8, 2013
P=N/A, N=1240, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=200 --> 1240 Recruiting --> Active, not recruiting
- |||| rontalizumab (RG7415) / Roche
Trial completion: A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (clinicaltrials.gov) - Sep 8, 2013
P2, N=238, Completed, Sponsor: Genentech
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change: Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia (clinicaltrials.gov) - Sep 8, 2013
P3, N=65, Completed, Sponsor: Copenhagen University Hospital at Herlev
Active, not recruiting --> Completed N=100 --> 65
- Enrollment closed: Incidence of Hypoglycemia During Ramadan in Patients With Type1 Diabetes on Insulin Pump Versus Multi Dose Injection (clinicaltrials.gov) - Sep 8, 2013
P=N/A, N=142, Active, not recruiting, Sponsor: Reem Mohammad Alamoudi
N=100 --> 65 Not yet recruiting --> Active, not recruiting
- Enrollment closed: Short Term Closed-loop Glucose Control in Adults With Type 1 Diabetes (clinicaltrials.gov) - Sep 8, 2013
P2, N=18, Active, not recruiting, Sponsor: University of Cambridge
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia (clinicaltrials.gov) - Sep 8, 2013
P3, N=65, Completed, Sponsor: Copenhagen University Hospital at Herlev
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| tabalumab (LY2127399) / Eli Lilly
Enrollment closed: A Study of LY2127399 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - Sep 5, 2013
P3, N=1140, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| NN9828 / Novo Nordisk
Trial completion: A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Sep 5, 2013
P2, N=62, Completed, Sponsor: Novo Nordisk
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Clinical data, Trial completion, Combination therapy: A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov) - Sep 5, 2013
P3, N=1262, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Humira (adalimumab) / AbbVie, Tavalisse (fostamatinib) / Rigel
Trial termination, Monotherapy: OSKIRA -4: Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Sep 5, 2013
P2b, N=390, Terminated, Sponsor: AstraZeneca
Active, not recruiting --> Completed Recruiting --> Terminated; AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.
- | Tavalisse (fostamatinib) / Rigel
Trial termination: OSKIRA-X: Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Sep 5, 2013
P3, N=1917, Terminated, Sponsor: AstraZeneca
Recruiting --> Terminated; AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals. Recruiting --> Terminated; AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.
- Trial completion: Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (France) (clinicaltrials.gov) - Sep 5, 2013
P=N/A, N=5, Completed, Sponsor: University of Virginia
Recruiting --> Terminated; AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals. Recruiting --> Completed
- Trial completion: Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (Italy) (clinicaltrials.gov) - Sep 5, 2013
P=N/A, N=5, Completed, Sponsor: University of Virginia
Recruiting --> Completed Recruiting --> Completed
- ||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion: SKORE: Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® (clinicaltrials.gov) - Sep 4, 2013
P=N/A, N=300, Completed, Sponsor: Merck KGaA
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker (clinicaltrials.gov) - Sep 4, 2013
P=N/A, N=12, Completed, Sponsor: University of Virginia
Active, not recruiting --> Completed N=10 --> 12
- Trial completion: Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker (clinicaltrials.gov) - Sep 4, 2013
P=N/A, N=12, Completed, Sponsor: University of Virginia
N=10 --> 12 Recruiting --> Completed
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Sep 4, 2013
P3, N=188, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
New P3 trial: A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Sep 3, 2013
P3, N=584, Active, not recruiting, Sponsor: Samsung Bioepis Co., Ltd.
- Trial withdrawal: Gene Polymorphisms Influencing Steroid Synthesis and Action (clinicaltrials.gov) - Sep 3, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Schleswig-Holstein
Active, not recruiting --> Completed Recruiting --> Withdrawn
- Enrollment change: Gene Polymorphisms Influencing Steroid Synthesis and Action (clinicaltrials.gov) - Sep 3, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Schleswig-Holstein
Recruiting --> Withdrawn N=500 --> 0
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes (clinicaltrials.gov) - Sep 2, 2013
P1, N=43, Completed, Sponsor: Novo Nordisk
- ||| GSK3117391 / GSK
New P1 trial: Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers (clinicaltrials.gov) - Sep 2, 2013
P1, N=94, Recruiting, Sponsor: GlaxoSmithKline
- Enrollment open: BHYRRA: Effect Assessment of Periodontal Prophylaxis on Rheumatoid Arthritis Activity. (clinicaltrials.gov) - Sep 1, 2013
P=N/A, N=200, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
N=500 --> 0 Not yet recruiting --> Recruiting
- Trial completion: Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (clinicaltrials.gov) - Sep 1, 2013
P=N/A, N=9, Completed, Sponsor: University of Virginia
Not yet recruiting --> Recruiting Recruiting --> Completed
- Preclinical, Trial termination: [18F]PBR111 and Microglial Activation in Multiple Sclerosis (clinicaltrials.gov) - Aug 29, 2013
P2, N=50, Terminated, Sponsor: GlaxoSmithKline
Recruiting --> Completed Recruiting --> Terminated; The Study was terminated because there was insufficient data to complete the study objectives
- prezalumab (AMG 557) / Amgen, AstraZeneca
Trial initiation date: Safety Study of AMG 557 in Subjects With Lupus Arthritis (clinicaltrials.gov) - Aug 29, 2013
P1, N=40, Recruiting, Sponsor: Amgen
Recruiting --> Terminated; The Study was terminated because there was insufficient data to complete the study objectives Initiation date: Jan 2012 --> Jun 2012
- New P1 trial: Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis (clinicaltrials.gov) - Aug 29, 2013
P1, N=20, Recruiting, Sponsor: Tisch Multiple Sclerosis Research Center of New York
- arsenic trioxide / Generic mfg.
P2a data, Trial initiation date: Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC) (clinicaltrials.gov) - Aug 28, 2013
P2, N=13, Recruiting, Sponsor: Nantes University Hospital
Initiation date: Jan 2012 --> Jun 2012 Initiation date: Dec 2012 --> Jul 2013
- ||| BIIB023 / Biogen
Trial initiation date: ATLAS: BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis (clinicaltrials.gov) - Aug 28, 2013
P2, N=300, Recruiting, Sponsor: Biogen Idec
Initiation date: Dec 2012 --> Jul 2013 Initiation date: Jan 2012 --> Jul 2012
- New P1 trial: SIAMMS-II: Repeat Infusion of Autologous Bone Marrow Cells in Multiple Sclerosis (clinicaltrials.gov) - Aug 28, 2013
P1, N=6, Not yet recruiting, Sponsor: North Bristol NHS Trust
- Trial completion: Telephone Intervention for Pain Study (TIPS) (clinicaltrials.gov) - Aug 28, 2013
P=N/A, N=207, Completed, Sponsor: University of Washington
Initiation date: Jan 2012 --> Jul 2012 Active, not recruiting --> Completed
- ||| tibulizumab (ZB-106) / Zura Bio
Enrollment open: A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Aug 28, 2013
P1, N=51, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| BI 655064 / AbbVie, Boehringer Ingelheim
Enrollment open: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy (clinicaltrials.gov) - Aug 28, 2013
P1, N=106, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||||| New P4 trial: Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns (clinicaltrials.gov) - Aug 27, 2013
P4, N=240, Recruiting, Sponsor: Allergan
- ||||| BIIB023 / Biogen
New P2 trial: BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis (clinicaltrials.gov) - Aug 27, 2013
P2, N=175, Enrolling by invitation, Sponsor: Biogen Idec
- Enrollment open: Accuracy Characterization Study (clinicaltrials.gov) - Aug 27, 2013
P=N/A, N=30, Recruiting, Sponsor: Abbott Diabetes Care
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial withdrawal: ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon (clinicaltrials.gov) - Aug 26, 2013
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Enrollment change: ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon (clinicaltrials.gov) - Aug 26, 2013
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Withdrawn N=200 --> 0